title: Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation.
abstract: The number of CD34+ cells has been described as the best parameter for predicting the quality of engraftment in peripheral blood progenitor cell (PBPC) transplantation in the early post-transplant period. In this study we have determined the optimal number of CD34+cells in order to maintain engraftment in the long term in a series of 100 patients receiving autologous PBPC transplantation. Based on our previous experience on the speed of early hematopoietic recovery, four subgroups of patients were established: patients infused less than 0.75 x 106/kg CD34+ (n = 9), 0.75 to 1.25 (n = 24), 1.25 to 2.0 (n = 37) and more than 2.0 (n = 30). These groups were designated as low, intermediate-low, intermediate-high and high CD34 groups, respectively. Transitory loss of neutrophil engraftment was observed in 67%, 30%, 16% and 6% of patients in the four mentioned CD34 groups respectively, with statistically significant differences between the different groups. Significant differences were also observed between the low CD34 group and the rest of the groups as regards platelet and red blood cell transfusion requirements, fever episodes, days of hospitalization and antibiotic requirements throughout the first year. Our results show that the dose of CD34+ cells influences engraftment also in the late post-transplant period, and correlates with transfusion and antibiotic requirements, fever episodes and days of hospitalization during the first year post-transplant.
authors.affiliation: Department of Hematology, University Hospital, Salamanca, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Pérez-Simón
authors.forename: A
authors.initials: A
authors.lastname: Martín
authors.forename: D
authors.initials: D
authors.lastname: Caballero
authors.forename: M
authors.initials: M
authors.lastname: Corral
authors.forename: M J
authors.initials: MJ
authors.lastname: Nieto
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: L
authors.initials: L
authors.lastname: Vazquez
authors.forename: C
authors.initials: C
authors.lastname: López-Berges
authors.forename: M C
authors.initials: MC
authors.lastname: Cañizo
authors.forename: M V
authors.initials: MV
authors.lastname: Mateos
authors.forename: A
authors.initials: A
authors.lastname: Orfao
authors.forename: J F
authors.initials: JF
authors.lastname: San Miguel
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018952:Antigens, CD34 / Q000097:blood* / Q000494:pharmacology*; D017707:Erythrocyte Transfusion; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006760:Hospitalization; D006801:Humans; D007239:Infections / Q000150:complications; D015999:Multivariate Analysis; D013997:Time Factors; D014182:Transplantation, Autologous
chemical_list: D000900:Anti-Bacterial Agents; D018952:Antigens, CD34